ORY Share Price Performance
€2.64
0.90 (52.14%)
Price €2.64
Share Price€2.64
ORY Community Narratives
There are no narratives available yet.
Recent ORY News & Updates
No updates
Oryzon Genomics S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.054
- Gross Margin
- 96.27%
- Net Profit Margin
- -56.48%
- Debt/Equity Ratio
- 15.8%
Oryzon Genomics S.A. Competitors
About ORY
- Founded
- 2000
- Employees
- 47
- CEO
- WebsiteView website
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Spanish Market Performance
- 7 Days: -0.1%
- 3 Months: 5.0%
- 1 Year: 30.5%
- Year to Date: 18.5%
The market has been flat in the last week, however the Energy sector is down 5.4%. Meanwhile, the market is actually up 31% over the past year. Looking forward, earnings are forecast to grow by 4.6% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading